In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis by Rolando Cimaz et al.
POSTER PRESENTATION Open Access
In vitro effects of etanercept on the development
of different T cell subsets in patients with
juvenile idiopathic arthritis
Rolando Cimaz*, Lorenzo Cosmi, Laura Maggi, Gabriele Simonini, Teresa Giani, Ilaria Pagnini, Veronica Santarlasci,
Manuela Capone, Valentina Querci, Francesco Liotta, Enrico Maggi, Francesco Annunziato
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Background
Recently, we found that CD4+CD161+ T lymphocytes
showing transient nature of the Th17 phenotype are
present in the synovial fluid of patients with JIA, and
that their accumulation positively correlates with para-
meters of inflammation, supporting the hypothesis that
these cells may play a role in disease activity.
Aim
In the present study, we assessed the ability of etaner-
cept to influence the in vitro development of different T
cell subsets in JIA patients. In particular, we have evalu-
ated the ability of peripheral blood (PB) and synovial
fluid (SF) lymphocytes from patients followed in our
Unit, to proliferate and produce cytokines in response
to polyclonal (antiCD3/antiCD28) stimulation in pre-
sence or in absence of etanercept.
Methods
Lymphocytes from PB and SF have been cultured in the
presence of etanercept (5 µg/ml), and proliferative
responses were evaluated as thimidine uptake and % of
bromodeoxyuridine positive cells. Cell phenotype by
flow cytometry and cytokine production (% of producing
cells) in CD4+ cells were also assessed.
Results
We have initially studied 11 patients with oligoarticular or
polyarticular JIA who underwent therapeutic arthrocent-
esis, with concomitant venipuncture for routine blood
tests. Administration in culture of etanercept did not signif-
icantly affect the proliferative response to aCD3/aCD28
stimulation of both PB- and SF-derived total CD4+ lym-
phocytes, whereas the presence in culture of etanercept
increased the frequency of proliferating CD4+CD161+ lym-
phocytes. Accordingly, etanercept in vitro administration
increased the frequency of total IL-17-producing CD4+ T
cells, leaving the IFN-gamma-producing ones unaffected.
Conclusions
These in vitro preliminary results seem to indicate that
etanercept is able to increase the frequency of IL-17
producing cells by favouring their proliferation.
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